Nintedanib, the only other marketed drug for IPF, is known to inhibit early events in TGF-β signaling, specifically the phosphorylation of TGF-β receptor 2 (TGFBR2) and Smad3 activation [66]. Here, SMAD3 is linked to idiopathic pulmonary fibrosis.